Oncology Archive

A building with a stone facade displays a sign that reads
A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer
A building with a stone facade displays a sign that reads
A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression
Internationally recognized oncology drug development leader and melanoma expert joins HonorHealth Research Institute
Pamela Jackson
A building with a stone facade displays a sign that reads
A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors
A doctor in a white coat gestures with both hands while speaking to a seated patient in a medical office with a window in the background.
New Clinical Trial Shows Nutrition Therapy Extends Survival by 34% in Stage IV Pancreatic Cancer Patients
A building with a stone facade displays a sign that reads
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)
A building with a stone facade displays a sign that reads
A Phase 1/2, Dose Escalation and Expansion Trial to Evaluate the Safety and Efficacy of Tegavivint in Patients with Metastatic Colorectal Carcinoma
A building with a stone facade displays a sign that reads
An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
A building with a stone facade displays a sign that reads
A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)